Enovis Corporation (ENOV)
NYSE: ENOV · Real-Time Price · USD
18.99
+0.74 (4.05%)
At close: Oct 13, 2026, 4:00 PM EDT
18.99
0.00 (0.00%)
After-hours: Oct 13, 2026, 7:00 PM EDT
Enovis Revenue
Enovis had revenue of $582.78M in the quarter ending July 3, 2026, with 3.23% growth. This brings the company's revenue in the last twelve months to $2.30B, up 4.89% year-over-year. In the year 2025, Enovis had annual revenue of $2.25B with 6.66% growth. That makes Enovis the 4,543rd largest company in the world by revenue and 1,215th in the United States.
Revenue (ttm)
$2.30B
Revenue Growth
+4.89%
P/S Ratio
0.47
Revenue / Employee
$294,361
Employees
7,802
Market Cap
1.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.25B | 140.43M | 6.66% |
| Dec 31, 2024 | 2.11B | 400.43M | 23.46% |
| Dec 31, 2023 | 1.71B | 144.10M | 9.22% |
| Dec 31, 2022 | 1.56B | 136.91M | 9.60% |
| Dec 31, 2021 | 1.43B | -1.64B | -53.56% |
| Dec 31, 2020 | 3.07B | -256.69M | -7.71% |
| Dec 31, 2019 | 3.33B | 1.13B | 51.73% |
| Dec 31, 2018 | 2.19B | -1.11B | -33.55% |
| Dec 31, 2017 | 3.30B | 114.43M | 3.59% |
| Dec 31, 2016 | 3.19B | -781.30M | -19.69% |
| Dec 31, 2015 | 3.97B | -657.42M | -14.22% |
| Dec 31, 2014 | 4.62B | 417.27M | 9.92% |
| Dec 31, 2013 | 4.21B | 293.35M | 7.50% |
| Dec 31, 2012 | 3.91B | 3.22B | 464.45% |
| Dec 31, 2011 | 693.39M | 151.41M | 27.94% |
| Dec 31, 2010 | 541.99M | 16.96M | 3.23% |
| Dec 31, 2009 | 525.02M | -79.83M | -13.20% |
| Dec 31, 2008 | 604.85M | 98.55M | 19.46% |
| Dec 31, 2007 | 506.31M | 112.70M | 28.63% |
| Dec 31, 2006 | 393.60M | 48.13M | 13.93% |
| Dec 31, 2005 | 345.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| QuidelOrtho | 2.67B |
| Integra LifeSciences Holdings | 1.65B |
| Lumexa Imaging Holdings | 1.04B |
| Tandem Diabetes Care | 1.04B |
| Bioventus | 581.85M |
| Artivion | 471.47M |
| PROCEPT BioRobotics | 337.34M |
| SI-BONE | 213.60M |
ENOV News
- 1 day ago - Enovis price target lowered to $34 from $52 at Needham - TheFly
- 5 days ago - Enovis to Host Third Quarter 2026 Results Conference Call on November 5th - GlobeNewsWire
- 21 days ago - Enovis becomes first multi-registry industry sponsor of AAOS Registry Program - PRNewsWire
- 26 days ago - Enovis management to meet virtually with Freedom Capital - TheFly
- 5 weeks ago - Enovis Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 5 weeks ago - Enovis price target lowered to $36 from $40 at BTIG - TheFly
- 5 weeks ago - Enovis price target lowered to $47 from $55 at Citizens - TheFly
- 6 weeks ago - Enovis price target lowered to $36 from $40 at BTIG - TheFly